Datapoint: GSK Expands Jemperli’s Oncology Reach

The FDA last week granted accelerated approval to GlaxoSmithKline’s Jemperli for the treatment of mismatch repair deficient (dMMR) solid tumors that have progressed despite previous treatment. The PD-1 drug was initially approved in April 2021 for previously treated dMMR endometrial cancer. It holds 55% covered or better status under the medical benefit, and 18% covered or better status under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 8/23/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 24

Datapoint: Florida Adds Three More MCOs to Medicaid Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 23

Datapoint: Rhode Island Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 22

Datapoint: Georgia Medicaid Work Program Sees Slow Start

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today